secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2026-06-22T13:02:23+00:00
Accession:  0001437749-26-021262
Event type: other_material
Sentiment:  positive
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex receives Canadian patent allowance for REQORSA combo with PD-1/PD-L1 in lung cancer
--------------------------------------------------------------------------------

- Canadian IPO issued Notice of Allowance for patent covering REQORSA with PD-1/PD-L1 antibodies for NSCLC and SCLC.
- Patent expands existing IP portfolio for Acclaim-3 trial evaluating REQORSA combinations.
- Canadian Cancer Society estimates 32,900 new lung cancer cases in 2026; 19,300 deaths.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926021262/0001437749-26-021262-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926021262/gnpx20260619_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-021262

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer